BlackRock, Inc. 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Celldex Therapeutics, Inc. CLDX |
BlackRock Inc. BLK |
4,819,293 7.300% |
-661,377 (-12.07%) |
Filing |
| 2025-02-05 1:23 pm Purchase |
2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
BlackRock Inc. BLK |
5,480,670 8.300% |
1,804,978 (+49.11%) |
Filing |
| 2024-01-26 5:25 pm Purchase |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
BlackRock Inc. BLK |
3,675,692 6.700% |
450,976 (+13.98%) |
Filing |
| 2023-01-31 5:52 pm Purchase |
2022-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
BlackRock Inc. BLK |
3,224,716 6.800% |
123,686 (+3.99%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
BlackRock Inc. BLK |
3,101,030 6.600% |
3,101,030 (New Position) |
Filing |